Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of ENX-101 in healthy volunteers
NL-OMON51175Phase 1Completed
- Sponsor
- Engrail Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy, Muscle spasm and anxiety disorder comparing ENX-101 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Apr 2021; status: completed.
02
Drugs
ENX-101
03
Conditions
epilepsyMuscle spasmanxiety disorder
Beyond the preview
Go deeper on NL-OMON51175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51175.